Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Caskey (OPP1196351; INV-008818): Phase 1 Clinical Study Testing GT1.1 Trimer |
| Strategy: | Protein & peptide vaccines |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | In progress |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A randomized, double-blinded, placebo-controlled, dose-escalation Phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 vaccine, adjuvanted in healthy HIV-uninfected adults
Description
CAVD 820 (IAVI C101) is a Phase 1 clinical trial to evaluate the safety and immunogenicity of BG505 SOSIP.GT1.1 gp140 vaccine, adjuvanted with AS01B.
Sign in to see full information about this study and to download study data.
Products
AS01B BG505 SOSIP.GT1.1 Tris-NaCl DiluentIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.